+

WO1996036881A2 - Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) - Google Patents

Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) Download PDF

Info

Publication number
WO1996036881A2
WO1996036881A2 PCT/GB1996/001165 GB9601165W WO9636881A2 WO 1996036881 A2 WO1996036881 A2 WO 1996036881A2 GB 9601165 W GB9601165 W GB 9601165W WO 9636881 A2 WO9636881 A2 WO 9636881A2
Authority
WO
WIPO (PCT)
Prior art keywords
mhc
tcr
peptide
peptide ligand
cell
Prior art date
Application number
PCT/GB1996/001165
Other languages
English (en)
Other versions
WO1996036881A3 (fr
Inventor
Dan Hung Barouch
Stephen John Rupert Vessey
Bent Karsten Jakobsen
Original Assignee
Cancer Research Campaign Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Limited filed Critical Cancer Research Campaign Technology Limited
Priority to AU57690/96A priority Critical patent/AU5769096A/en
Publication of WO1996036881A2 publication Critical patent/WO1996036881A2/fr
Publication of WO1996036881A3 publication Critical patent/WO1996036881A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Definitions

  • This invention relates to interactions between T-cell receptors and their specific MHC/peptide ligand and the potential therapeutic applications of inhibitors of this interaction.
  • TCRs T-cell receptors
  • MHC- peptide ligands MHC- peptide ligands
  • the responder cell expressing the TCR preferably has the following properties: (i) it should be easy to culture; (ii) the correctly folded TCR should be stably expressed at high levels on the cell surface; (iii) the signal generated by the TCR-MHC interaction should be easily detectable by conventional means and simulates the functioning of the TCR in its native T- cell environment.
  • An example of such a responder cell is a mast cell transfected with recombinant DNA encoding the TCR protein and which undergoes degranulation in response to the TCR-MHC interaction on the cell surface.
  • Stimulatory MHC-peptide complexes may be created by immobilising soluble recombinant MHC on a solid support, such as "Dynabeads" (a form of plastic beads).
  • the MHC is typically obtained by recombinant DNA expression, and is a single specific MHC molecule or fragment thereof.
  • the present invention is based upon the following experimental data.
  • TCR T cell receptor
  • Figure la shows the cloning and expression of TCR genes encoding V ⁇ 2.2 and VjSl.l.
  • Figure lb shows the FACS analysis of stably transfected RBLs expressing the TCZR.
  • Figure lc shows, in the preparation and purification of MHC-peptide complexes, a sample HPLC gel filtration profile of purified, soluble, recombinant MHC protein.
  • Figure 2a-d shows specific response of RBL/TCZR transfectants to peptide-pulsed target cells and purified MHC proteins. The results are means from triplicate assays. A typical experiment is shown in each case.
  • Figure 3a-f shows competition with monomeric MHC-peptide complexes and controls.
  • Figure 4 shows diagrammatically a model for TCZR signalling.
  • TCR genes were amplified by PCR from cDNA prepared from a CTL clone specific for HLA A2.1 restricted HIV pol peptide.
  • Primer sequences were: V ⁇ 2.2 forward (5' CAC CGC TCG AGC CGC CAT CAT GAT GAA ATC CTT GAG A 3'), Nc.2.2 back (5' CTG GTA CAC GGC CGG GTC AGG GTT CTG GAT ATT 3')
  • VjSl.l forward (5'ATG CAA GTC AGT CGA CCC GCC ACC ATG GGC TTC AGG CTC CTC T 3'), and VjSl.
  • Stable transfectants were selected by the addition of 700 g/ml G418 (Sigma), 15 ⁇ g/ml hypoxanthine, lO ⁇ g/ml aminopterin, 2 ⁇ g/ml thymidine, 250 ⁇ g/ml xanthine and 5 ⁇ g/ml mycophenolic acid.
  • Protein concentrations were determined by a combination of spectrophotometry, scanning densitometry on SDS-PAGE gels, and HPLC peak quantitation. The concentrations of active protein in each preparation were confirmed by an ELISA detecting immobilized MHC protein with a panel of monoclonal antibodies (data not shown).
  • peptides complexed with the A2 proteins were: pol (ILKEPVHGV), gag (SLYNTVATL), a random library of A2-binding peptides, pol-8E (ILKEPVHEV), a self peptide TLW (TLWVDPYEV), and null (SLAAAAAAL).
  • RBLs were cultured in flat bottomed 96 well plates (Falcon) at a density of 5x10"* cells/well for 12 hours at 37°C in DMEM 10%FCS (Sigma) with 3 H-hydroxytryptamine creatinine sulphate (DuPont) at a final concentration of 0.2 / xCi/ml.
  • the RBLs were washed 3 times in warm DMEM 10%FCS, incubated or 20 mins and then washed once more.
  • C1R cells were resuspended at 5xl0 6 /100 ⁇ l and pulsed with various concentrations of peptide for 2hrs at 37°C. After one wash these APCs were added to the RBLs and coincubated for 60mins at 37° C. Supernatants were collected and responses were measured as corrected counts per minute (ccpm) by liquid scintillation counting.
  • Figure 2a shows the response to HA-A2.1 C1R cells pulsed with a range of concentrations of the HIV pol peptide.
  • Figure 2b shows the response to HA-A2.1 or HA-B7 C1R cells pulsed with individual peptides.
  • Degranulation assays were performed as above except either monomeric MHC protein or 10 million MHC-saturated dynabeads were added to the wells instead of peptide-pulsed cells.
  • sheep anti-mouse dynabeads were first saturated with an affinity-purified monoclonal coupling antibody according to manufacturer's protocols (Dynal). Coupling antibodies used were W6/32 (monomorphic anti- MHC) and BB7.2 (anti-A2, directed against the alpha-2 helix of the MHC). Following three washes, the beads were saturated with MHC-peptide complexes for 2 hours at 4° and then washed again three times before addition to the assay.
  • Biotinylated A2-peptide complexes were prepared by surface biotinylation of refolded ⁇ 2M protein for 1 hour at room temperature using a 3-fold molar excess of NHS- SS-biotin (Pierce) gel filtration purification to remove free biotin, and seeding a folding reaction essentially as before (Fig lc) using folded biotinylated ⁇ 2M, denatured heavy chain, and a synthetic peptide.
  • Results shown are means of 3 to 8 independent experiments each performed in duplicate and are reported as a percent of the uncompeted response. Standard error of the mean is shown in Fig 3a.
  • Degranulation assays were performed (as in Fig 2) using 10 million A2-pol coated streptavidin dynabeads (as in Fig 2d) per well.
  • a sub-saturating concentration of MHC protein was used (l ⁇ g MHC per 10 million beads), and the response with no added competitor was approximately 1000 ccpm.
  • Soluble, monomeric, non-biotinylated MHC protein was checked by gel filtration to ensure that there was no detectable aggregation of the protein.
  • the protein was diluted in media and added to the assay together with the A2- pol coated dynabeads.
  • Figure 3c shows that the stimulatory capacity of streptavidin coated dynabeads bearing multivalent arrays of MHC-peptide is unaffected by preincubation with monomeric complexes.
  • Biotinylated A2-pol or A2-gag complexes were linked to streptavidin coated dynabeads as described above. Beads were then incubated for 60 mins at 37°C with either medium alone or 10 ⁇ M non-biotinylated monomeric complexes.
  • Multivalent A2-pol was incubated with monomeric A2-gag and vice versa. After washing the beads 3 times in warm DMEM 10% FCS to remove free monomeric complexes they were used in degranulation assays as described above.
  • Figure 3d shows that the response to multivalent A2-pol is unaffected by the presence of free gag peptide. Assays were performed as described above in the presence of ascending concentrations of uncomplexed gag peptide.
  • Figure 3f shows that RBL/TCZR degranulation is unaffected by preincubation of transfectants with monomeric MHC-peptide complexes.
  • RBL/TCZR transfectants were preincubated with monomeric MHC-peptide complexes for 40 mins at 37 °C and men washed with warm DMEM 10% FCS. Degranulation assays were then performed as in Fig 2 but with 10 million streptavidin dynabeads coated with A2-pol per well.
  • Figure 4 proposes a model for TCZR signalling based on the results presented here together with the findings in references 20-22 and possible similarities with the EGF receptor 23 .
  • Figure 4a shows TCZR engaged by a multivalent array of MHC-peptide complexes.
  • Figure 4b shows how specific ligand can induce conformational change allowing stable receptor aggregation. Non-specific ligand induces no conformational change.
  • Figure 4c shows TCZR engaged by soluble monomeric MHC-peptide complexes.
  • Figure 4d shows conformational change induced, but insufficient cross-linking of receptors takes place. Results and discussion
  • Eukaryotic expression vectors encoding and ⁇ TCZR chimeric receptor chains 4 were constructed using TCR genes from a CTL clone specific for an HLA -A2.1 restricted HIV pol peptide (residues 476-484; ILKEPVHGV) 5 (Fig la).
  • Stably transfected RBL 2H3 cells expressing the TCZR (Fig lb) showed peptide specific and MHC restricted degranulation using peptide pulsed target cells (Fig 2a, b).
  • the response to multivalent A2-pol was also inhibited by monomeric soluble A2 protein complexed with some other peptides, including a variant of the index pol peptide, a random library of A2 binding peptides 8 , and a supposedly irrelevant HIV gag peptide pl7 (residues 77-85) 9 (Fig 3b).
  • monomeric soluble A2 protein complexed with some other peptides including a variant of the index pol peptide, a random library of A2 binding peptides 8 , and a supposedly irrelevant HIV gag peptide pl7 (residues 77-85) 9 (Fig 3b).
  • the present invention thus allows a very concise assay to be set up for the screening of substances, eg peptides or mimetics, that inhibit the interaction between TCRs and MHC- peptide ligands in vitro.
  • substances eg peptides or mimetics
  • the use of a RBL (a type of mast cell) expressing TCRs as repsonder cells is useful since degranulation of these cells provides a convenient signal of effective TCR-MHC-peptide interactions.
  • the RBLs are also useful in that other surface proteins are not known to interact with MHC, such as would be the case with T-cells which normally express TCRs.
  • other responder cells could be used, for example employing expression of a suitable reporter molecule such as jS-galactosidase as the detectable signal.
  • inhibitors of their binding could typically be highly specific peptides, MHC-peptide complexes or MHC-peptide mimetics, antibodies, TCRs, or other immunospecific molecules, or fragments of any of the above.
  • Other inhibitors could be more general in their action and inhibit many or all TCR-MHC interactions. These inhibitors could act by direct competition, allosteric changes, or other means.
  • TCR-MHC-peptide interactions could be used in a variety of therapeutic applications, for example in blocking T-cells which give rise to autoimmune disease such as diabetes, rheumatoid arthritis, groves disease etc, organ transplant rejection, or other T-cell mediated conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne les interactions entre les RLT et leur ligand CMH-peptide spécifique. Un procédé d'évaluation préliminaire permet d'identifier les substances qui inhibent l'interaction spécifique entre le RLT et un ligand CMH-peptide: il consiste à incuber des cellules sensibles exprimant un RLT avec (i) un ligand CMH-peptide qui stimule ces cellules sensibles et (ii) une substance potentiellement inhibitrice; à mesurer le signal produit par les cellules sensibles quand le RLT entre en contact avec le ligand CMH-peptide; et à comparer le signal produit par ces cellules sensibles, lors du contact du RLT avec le ligand CMH-peptide, avec un signal de référence obtenu avec les mêmes cellules sensibles lorsqu'elles sont incubées avec (i) mais sans (ii). La diminution du signal associée à la présence de (ii) dans le milieu d'incubation représente l'efficacité de l'inhibiteur.
PCT/GB1996/001165 1995-05-16 1996-05-16 Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) WO1996036881A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57690/96A AU5769096A (en) 1995-05-16 1996-05-16 Screening for inhibitors of tcr-mhc interactions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9509844.8 1995-05-16
GBGB9509844.8A GB9509844D0 (en) 1995-05-16 1995-05-16 Screening for inhibitors of TCR-MHC interactions

Publications (2)

Publication Number Publication Date
WO1996036881A2 true WO1996036881A2 (fr) 1996-11-21
WO1996036881A3 WO1996036881A3 (fr) 1997-01-09

Family

ID=10774510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001165 WO1996036881A2 (fr) 1995-05-16 1996-05-16 Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)

Country Status (3)

Country Link
AU (1) AU5769096A (fr)
GB (1) GB9509844D0 (fr)
WO (1) WO1996036881A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
EP0833941A1 (fr) * 1995-04-07 1998-04-08 Cytogen Corporation Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
WO1999038526A1 (fr) * 1998-01-29 1999-08-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variants de ligands peptidiques induisant selectivement l'apoptose
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
WO2001090747A2 (fr) * 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation des interactions des recepteurs des cellules t
WO2020028595A3 (fr) * 2018-07-31 2020-04-23 Janux Therapeutics, Inc. Peptides inhibiteurs de récepteur de lymphocyte t et procédés de découverte

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016234A1 (fr) * 1991-03-22 1992-10-01 The Trustees Of The University Of Pennsylvania Procede de modulation de la reaction de lymphocytes t de mammiferes
WO1995007707A1 (fr) * 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016234A1 (fr) * 1991-03-22 1992-10-01 The Trustees Of The University Of Pennsylvania Procede de modulation de la reaction de lymphocytes t de mammiferes
WO1995007707A1 (fr) * 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGICAL RESEARCH, vol. 11, no. 1, March 1992, BASEL, SWITZERLAND, pages 11-23, XP002015728 W. WILLIAMS ET AL.: "Modulation of T cell responses with MHC-derived peptides." *
NATURE, vol. 356, 30 April 1992, LONDON, GB, pages 793-796, XP002008364 S. WEBER ET AL.: "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor." *
SCIENCE, vol. 267, no. 5197, 27 January 1995, WASHINGTON, DC, USA, pages 515-518, XP002015729 J. MADRENAS ET AL.: "Zeta phosphorylation without ZAP-70 activation induced by TcR antagonists or partial agonists." *
THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 6, 1 June 1993, NEW YORK, NY, USA, pages 1541-1550, XP000604978 S. JAMESON ET AL.: "Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells." *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833941A1 (fr) * 1995-04-07 1998-04-08 Cytogen Corporation Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
US6709821B2 (en) 1995-04-07 2004-03-23 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
EP0833941A4 (fr) * 1995-04-07 2004-12-08 Cytogen Corp Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
US7223547B2 (en) 1995-04-07 2007-05-29 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
WO1997044667A3 (fr) * 1996-05-21 1998-03-19 Pasteur Institut Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules T antigene-specifiques et pour stimuler des cellules T
WO1999038526A1 (fr) * 1998-01-29 1999-08-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variants de ligands peptidiques induisant selectivement l'apoptose
WO2001090747A2 (fr) * 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation des interactions des recepteurs des cellules t
WO2001090747A3 (fr) * 2000-05-25 2002-07-11 Sunol Molecular Corp Modulation des interactions des recepteurs des cellules t
WO2020028595A3 (fr) * 2018-07-31 2020-04-23 Janux Therapeutics, Inc. Peptides inhibiteurs de récepteur de lymphocyte t et procédés de découverte
US20210371849A1 (en) * 2018-07-31 2021-12-02 Janux Therapeutics, Inc. Inhibitory t cell receptor peptides and discovery methods

Also Published As

Publication number Publication date
WO1996036881A3 (fr) 1997-01-09
GB9509844D0 (en) 1995-07-12
AU5769096A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
Rich et al. Survey of the year 2007 commercial optical biosensor literature
Salter et al. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2
Maenaka et al. MHC superfamily structure and the immune system
Reijonen et al. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes
Fischer et al. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CDS+ thymocytes
Pereira et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?
Shen et al. Channel catfish NK-like cells are armed with IgM via a putative FcμR
Chen et al. Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation.
Altman et al. MHC‐peptide tetramers to visualize antigen‐specific T cells
US20240294601A1 (en) Peptide deficient-mhc class i/chaperone compositions and methods
Esteban et al. Directed evolution of soluble single-chain human class II MHC molecules
Henson et al. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function
Greten et al. Peptide–β2-microglobulin–MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC–Ig complexes
EP3658683A1 (fr) Découverte d'épitopes à médiation par trogocytose
Sim et al. Innate receptors with high specificity for HLA class I–peptide complexes
WATSON et al. Identification of a polymorphism in the human neurotensin receptor gene
Wen et al. Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display
WO1996036881A2 (fr) Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)
Tomas et al. Clustering of a lipid-raft associated pool of ERM proteins at the immunological synapse upon T cell receptor or CD28 ligation
DeBell et al. Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a
Gibbings et al. CD8α is expressed by human monocytes and enhances FcγR-dependent responses
Busch et al. Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers
Blaher et al. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen
US7442773B2 (en) Universal peptide-binding scaffolds and protein chips
US20230059548A1 (en) Systems and methods for identification of mhc-i peptide epitopes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载